Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Escitalopram
Drug ID BADD_D00809
Description Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram].[A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class.[A185726] Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822]
Indications and Usage Escitalopram is indicated for both acute and maintenance treatment of major depressive disorder (MDD) and for the acute treatment of generalized anxiety disorder (GAD).[L8513] It is additionally indicated for symptomatic relief of obsessive-compulsive disorder (OCD) in Canada.[L8516]
Marketing Status approved
ATC Code N06AB10
DrugBank ID DB01175
KEGG ID D07913
MeSH ID D000089983
PubChem ID 146570
TTD Drug ID D08RBC
NDC Product Code 80425-0320; 50090-4915; 51655-284; 53002-1431; 67296-1200; 0456-2010; 0456-2020; 69097-848; 70518-1785; 71335-1030; 0615-8366; 42708-163; 45865-699; 55700-847; 69844-079; 72189-424; 72189-451; 16729-168; 43547-281; 43547-282; 61919-652; 63187-281; 68001-456; 68071-5248; 68788-7461; 69844-077; 70934-630; 68001-454; 68071-2035; 68645-520; 68788-7510; 69844-078; 70934-957; 71205-344; 71610-425; 71610-534; 72189-449; 16571-755; 16729-170; 50090-2196; 51655-236; 53002-2438; 60760-393; 68788-7912; 70518-2317; 70771-1145; 71335-1002; 71335-1187; 71335-1307; 16571-757; 51655-766; 54838-551; 70518-2430; 70771-1147; 50090-4363; 50090-5312; 50090-6534; 51655-116; 51655-149; 69097-847; 69097-849; 70518-1876; 71205-325; 76282-250; 76282-251; 42708-155; 50090-1930; 70518-2472; 70518-3151; 70771-1146; 82982-030; 43547-280; 50090-6190; 51655-277; 55700-818; 63187-217; 67296-1597; 68001-455; 68645-519; 0456-2005; 70518-1805; 70518-2597; 71335-1571; 72189-438; 0615-8365; 72789-194; 76282-249; 16571-756; 33342-053; 60760-170; 65162-705; 71205-782; 71335-1241; 71335-2058; 0615-8348; 16729-169; 43063-661
UNII 4O4S742ANY
Synonyms Escitalopram | Escitalopram Oxalate | Lexapro
Chemical Information
Molecular Formula C20H21FN2O
CAS Registry Number 128196-01-0
SMILES CN(C)CCCC1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000057%Not Available
Pancreatic neuroendocrine tumour16.24.02.005; 07.21.09.009; 05.08.01.0140.000019%Not Available
Decreased eye contact19.01.02.012; 17.02.05.0550.000038%Not Available
Motor developmental delay19.22.01.005; 17.01.02.0230.000028%Not Available
Distributive shock24.06.02.0220.000038%Not Available
Respiratory muscle weakness22.09.01.004; 17.05.03.017; 15.05.06.0030.000019%Not Available
Seizure like phenomena17.12.03.0300.000019%Not Available
Psychological trauma19.01.02.0170.000028%Not Available
Stiff person syndrome15.05.04.021; 10.04.10.017; 17.05.02.0180.000038%Not Available
Invasive ductal breast carcinoma21.05.01.021; 16.10.01.0130.000019%Not Available
Lobular breast carcinoma in situ16.10.01.015; 21.05.01.0230.000047%Not Available
Decerebrate posture15.03.05.008; 17.02.05.0540.000019%Not Available
Gluten sensitivity14.02.01.008; 10.01.01.031; 07.17.01.0090.000097%Not Available
Infantile apnoea22.11.02.004; 18.04.15.0030.000076%Not Available
Selective eating disorder19.09.01.012; 14.03.02.0240.000047%Not Available
Allergic reaction to excipient10.01.01.0350.000064%Not Available
Anisocoria17.02.11.009; 06.05.03.0130.000051%Not Available
Antidepressant discontinuation syndrome08.06.02.0210.000019%Not Available
Attention deficit hyperactivity disorder19.21.04.0040.000028%Not Available
Behaviour disorder19.01.01.0050.000066%Not Available
Constricted affect19.04.01.0060.000066%Not Available
Craniofacial fracture15.08.04.004; 12.04.05.005--Not Available
Drug use disorder19.07.06.0120.000028%Not Available
Electric shock sensation17.02.07.024; 08.06.02.023--Not Available
Fear of injection19.06.03.016--Not Available
Fear-related avoidance of activities19.06.03.0190.000038%Not Available
Graves' disease10.04.08.014; 06.09.04.009; 05.02.02.0090.000019%Not Available
Heavy menstrual bleeding21.01.03.005--Not Available
Hepatic cytolysis09.01.07.0360.000104%Not Available
Immune thrombocytopenia10.02.01.083; 01.08.01.013--Not Available
The 35th Page    First    Pre   35 36    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene